CN108699148A - 配制用于向人施用的抗cd28人源化抗体 - Google Patents

配制用于向人施用的抗cd28人源化抗体 Download PDF

Info

Publication number
CN108699148A
CN108699148A CN201680080258.4A CN201680080258A CN108699148A CN 108699148 A CN108699148 A CN 108699148A CN 201680080258 A CN201680080258 A CN 201680080258A CN 108699148 A CN108699148 A CN 108699148A
Authority
CN
China
Prior art keywords
weeks
fab
once
optional
antibody fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680080258.4A
Other languages
English (en)
Chinese (zh)
Inventor
伯纳德·范霍夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSE Immunotherapeutics SA
Original Assignee
OSE Immunotherapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OSE Immunotherapeutics SA filed Critical OSE Immunotherapeutics SA
Publication of CN108699148A publication Critical patent/CN108699148A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201680080258.4A 2015-12-15 2016-12-15 配制用于向人施用的抗cd28人源化抗体 Pending CN108699148A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15200281 2015-12-15
EP15200281.2 2015-12-15
EP16306537.8 2016-11-22
EP16306537 2016-11-22
PCT/EP2016/081286 WO2017103003A1 (en) 2015-12-15 2016-12-15 Anti-cd28 humanized antibodies formulated for administration to humans

Publications (1)

Publication Number Publication Date
CN108699148A true CN108699148A (zh) 2018-10-23

Family

ID=57737702

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680080258.4A Pending CN108699148A (zh) 2015-12-15 2016-12-15 配制用于向人施用的抗cd28人源化抗体

Country Status (16)

Country Link
US (4) US20180215824A1 (cg-RX-API-DMAC7.html)
EP (2) EP3390450B1 (cg-RX-API-DMAC7.html)
JP (1) JP6923528B2 (cg-RX-API-DMAC7.html)
KR (2) KR20180087428A (cg-RX-API-DMAC7.html)
CN (1) CN108699148A (cg-RX-API-DMAC7.html)
CY (1) CY1124141T1 (cg-RX-API-DMAC7.html)
DK (1) DK3390450T3 (cg-RX-API-DMAC7.html)
ES (1) ES2862395T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210445T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053736T2 (cg-RX-API-DMAC7.html)
LT (1) LT3390450T (cg-RX-API-DMAC7.html)
PL (1) PL3390450T3 (cg-RX-API-DMAC7.html)
RS (1) RS61958B1 (cg-RX-API-DMAC7.html)
SI (1) SI3390450T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100185T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017103003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
JP2024531915A (ja) 2021-08-05 2024-09-03 ジーオー セラピューティクス,インコーポレイテッド 抗グリコmuc抗体およびその使用
WO2023034569A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
JP2024534910A (ja) 2021-09-03 2024-09-26 ジーオー セラピューティクス,インコーポレイテッド 抗グリコlamp1抗体およびその使用
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
EP4482865A1 (en) * 2022-02-24 2025-01-01 Xencor, Inc. Anti-cd28 x anti-trop2 antibodies
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1563092A (zh) * 2004-04-01 2005-01-12 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28单链三特异抗体
US20060003927A1 (en) * 2002-10-09 2006-01-05 Champion Brian R Modulation of immune function
CN1981031A (zh) * 2004-03-05 2007-06-13 宾久法尼亚大学理事会 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用
WO2011101791A1 (en) * 2010-02-18 2011-08-25 Tcl Pharma Anti-cd28 humanized antibodies
US20130230540A1 (en) * 2008-07-18 2013-09-05 Domantis Limited Compositions monovalent for cd28 binding and methods of use
CN103596593A (zh) * 2011-03-11 2014-02-19 贝丝以色列女执事医疗中心 抗cd40抗体及其用途
CN105073110A (zh) * 2013-03-25 2015-11-18 株式会社Lg生命科学 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060003927A1 (en) * 2002-10-09 2006-01-05 Champion Brian R Modulation of immune function
CN1981031A (zh) * 2004-03-05 2007-06-13 宾久法尼亚大学理事会 调节性t细胞及它们在免疫治疗和抑制自身免疫反应中的应用
CN1563092A (zh) * 2004-04-01 2005-01-12 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28单链三特异抗体
US20130230540A1 (en) * 2008-07-18 2013-09-05 Domantis Limited Compositions monovalent for cd28 binding and methods of use
WO2011101791A1 (en) * 2010-02-18 2011-08-25 Tcl Pharma Anti-cd28 humanized antibodies
CN103596593A (zh) * 2011-03-11 2014-02-19 贝丝以色列女执事医疗中心 抗cd40抗体及其用途
CN105073110A (zh) * 2013-03-25 2015-11-18 株式会社Lg生命科学 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
L G LUM等: "Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients", 《BONE MARROW TRANSPLANT》 *
L.H.BOOKBINDER等: "A recombinant human enzyme for enhanced interstitial transport of therapeutics", 《JOURNAL OF CONTROLLED RELEASE》 *
N POIRIER等: "FR104, an antagonist anti-CD28 monovalent fab" antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft", 《AM J TRANSPLANT》 *
N POIRIER等: "Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab" antibody", 《AM J TRANSPLANT》 *
李永琴等: "T细胞表面分子CD28及其信号通路的研究", 《贵阳医学院学报》 *
李永琴等: "抗CD28单克隆抗体诱导T细胞活化", 《中国病理生理杂志》 *
葛均波主编: "1.1.2-参与动脉粥样硬化发生的炎症细胞和介质", 《现代心脏病学》 *
邹雄等主编: "第三部分-免疫相关疾病", 《分子免疫学与临床》 *

Also Published As

Publication number Publication date
RS61958B1 (sr) 2021-07-30
SMT202100185T1 (it) 2021-05-07
ES2862395T3 (es) 2021-10-07
JP2018538309A (ja) 2018-12-27
SI3390450T1 (sl) 2021-08-31
CY1124141T1 (el) 2022-05-27
US20180215824A1 (en) 2018-08-02
LT3390450T (lt) 2021-06-25
US20250051446A1 (en) 2025-02-13
KR20240144440A (ko) 2024-10-02
EP3868785A1 (en) 2021-08-25
HUE053736T2 (hu) 2021-07-28
KR20180087428A (ko) 2018-08-01
HRP20210445T1 (hr) 2021-06-25
EP3390450A1 (en) 2018-10-24
US20220411510A1 (en) 2022-12-29
US20200115453A1 (en) 2020-04-16
EP3390450B1 (en) 2021-01-20
DK3390450T3 (da) 2021-03-01
JP6923528B2 (ja) 2021-08-18
WO2017103003A1 (en) 2017-06-22
PL3390450T3 (pl) 2021-09-13

Similar Documents

Publication Publication Date Title
US20220411510A1 (en) Anti-CD28 Humanized Antibodies Formulated for Administration to Humans
JP6861301B2 (ja) 移植片拒絶の予防に使用するための抗cd40抗体
TW201517917A (zh) 使用il-17拮抗劑治療類風濕性關節炎之方法
CN113271964A (zh) 化脓性汗腺炎治疗中使用的抗cd40抗体
JP2022116272A (ja) T1dm及び膵島炎の治療に使用するための抗cd40抗体
KR20170052526A (ko) 다발성 경화증에 대한 병용 치료
US20230242623A1 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
TW202311293A (zh) 免疫療法之組合及其用途
HK40058111A (en) Anti-cd28 humanized antibodies formulated for administration to humans
KR20230154239A (ko) 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체
US20220340687A1 (en) Methods of treatment using omalizumab
HK1260979A1 (en) Anti-cd28 humanized antibodies formulated for administration to humans
HK1260979B (en) Anti-cd28 humanized antibodies formulated for administration to humans
CN119630422A (zh) 使用白细胞介素-17(il-17)拮抗剂治疗巨细胞动脉炎的方法
WO2025029859A2 (en) Treatment of atopic dermatitis
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination